MTT Assay Workflow for Cell Viability

MTT, also known as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide), is a widely used tetrazolium salt for measuring viable-cell metabolic activity in vitro. As an in vitro cell proliferation assay reagent, it is especially valuable when researchers need a practical endpoint for screening cytotoxic compounds, comparing treatment schedules, or assessing whether a targeted delivery system changes cellular response.

The assay is powerful but not automatically synonymous with cell counting. MTT reports the capacity of living cells to reduce a tetrazolium substrate, so the result reflects metabolic activity as well as cell number. Careful plate design, reagent handling, and control selection are therefore essential when translating absorbance into viability or proliferation conclusions.

Setup: what the MTT signal means

Principle overview

MTT is membrane-permeable and cationic, allowing it to enter viable cells without an intermediate carrier. Inside the cell, mitochondrial NADH-dependent oxidoreductases are major contributors to reduction of MTT, while extra-mitochondrial enzymes can also contribute. The reaction produces insoluble purple formazan crystals. After the culture medium is removed, the crystals are dissolved and quantified by absorbance.

This makes MTT an NADH-dependent oxidoreductase substrate and a convenient colorimetric cell viability assay reagent. Under controlled conditions, higher formazan production generally indicates greater reducing capacity. However, a treatment that changes mitochondrial function without immediately changing cell number can shift the signal. For this reason, report the endpoint as relative metabolic activity unless cell-number calibration or an orthogonal assay supports a stronger interpretation.

Match the assay to the experimental question

For proliferation studies, seed cells uniformly and compare absorbance with a vehicle-treated growth control. For cytotoxicity studies, use multiple treatment concentrations and replicate wells. For radiation or nanoparticle experiments, MTT is best used as one layer of evidence alongside morphology, nuclear localization, clonogenic behavior, or another viability readout. The assay is destructive at the endpoint, so longitudinal experiments require separate replicate wells for each time point.

Key Innovation from the Reference Study

The reference study explored a localized chemoradiation strategy in which self-assembled micelles carried a caged, hydrophobic form of doxorubicin. Folate on the micelle surface supported cellular uptake, while X-ray exposure generated Cherenkov light that triggered photochemical release. The released drug became hydrophilic and was able to relocalize to the nucleus. In the reported design, an 8 Gy irradiation produced drug release and contributed to strong tumor-control effects with limited off-target organ damage, as described in the reference study.

The practical assay lesson is to separate delivery, activation, and biological response. An MTT experiment can quantify the viability consequence of irradiation, but it cannot by itself prove that release occurred, that the drug reached the nucleus, or that Cherenkov-triggered activation caused the effect. A useful design therefore includes untreated cells, free drug, unloaded micelles, caged-drug micelles without irradiation, and caged-drug micelles with irradiation. This converts MTT from a single endpoint into a decision tool for identifying whether toxicity depends on the carrier, the radiation trigger, or both.

Step-by-step workflow and protocol enhancements

Begin by confirming cell identity, passage consistency, and growth phase. Avoid comparing wells with markedly different confluence because density alters both reduction capacity and nutrient availability. Use a plate map that distributes treatment groups across the plate rather than placing one condition only at the edge or in a single row.

Protocol Parameters

• Cell seeding: Seed approximately 1,000–10,000 cells per well in 100 µL of complete medium in a 96-well plate, then allow 18–24 hours for attachment before treatment. Treat this as a starting range and optimize for the specific cell line.
• MTT preparation: Prepare a fresh aqueous stock at up to 2.5 mg/mL with ultrasonic assistance, or prepare a DMSO stock at 10 mg/mL. Add 10–20 µL per 100 µL well to target a practical final assay concentration of approximately 0.2–0.5 mg/mL.
• Reagent incubation: Incubate cells with MTT at 37 °C for 1–4 hours, protected from strong light. Inspect the wells for visible purple crystals before proceeding; incubation time should be shortened if untreated wells become excessively dark or cells show stress.
• Formazan solubilization: Remove the medium carefully without disturbing crystals, add 100 µL DMSO per well, and shake at approximately 300–600 rpm for 5–10 minutes until the color is visually uniform.
• Absorbance acquisition: Read the dissolved formazan near 570 nm and, when supported by the instrument, record a reference wavelength near 630–690 nm. Use the same optical settings, delay, and plate orientation for every experimental plate.

These conditions are practical starting points rather than universal specifications. The product information reports solubility of at least 41.4 mg/mL in DMSO, at least 18.63 mg/mL in ethanol, and at least 2.5 mg/mL in water with ultrasonic assistance; it also recommends storage at -20 °C and avoiding long-term storage of solutions. APExBIO supplies SKU B7777 at greater than 98% purity for research use. Prepare only the volume needed for the experiment, protect stock and working solutions from unnecessary light exposure, and document freeze-thaw history.

Include at least three technical or biological replicates per condition where plate capacity allows. Blank wells containing medium and MTT but no cells are needed for background correction. A vehicle control establishes the reference signal, while a treatment control with known cytotoxic activity can confirm that the assay responds within the selected cell-density range. Calculate relative metabolic activity as background-corrected treatment absorbance divided by background-corrected vehicle absorbance, multiplied by 100.

Advanced applications and comparative advantages

Applying MTT to radiation-triggered drug delivery

For the micelle-based chemoradiation concept, use a factorial layout: carrier versus no carrier, with versus without irradiation, and caged formulation versus an appropriate drug control. Collect the MTT endpoint at a biologically justified interval after treatment rather than immediately after irradiation, because release, nuclear trafficking, and downstream loss of metabolic capacity may occur on different timescales. If the reference condition uses 8 Gy, reproduce that dose only when the radiation platform and biological model are comparable; otherwise, treat it as a literature-defined benchmark rather than a universal prescription.

Nanoparticles and drug formulations can scatter light, absorb near the assay wavelength, or chemically reduce MTT outside cells. Add cell-free wells containing each formulation plus MTT and medium. If those wells develop color, subtracting a blank may not fully correct the result because particle interference can be nonlinear. In that situation, confirm the conclusion with imaging or a chemically distinct viability method.

Comparative advantages and boundaries

MTT is inexpensive, compatible with standard absorbance plate readers, and well suited to endpoint dose-response experiments. The insoluble formazan product can provide a strong signal after solubilization, making the assay practical for many adherent cell models. It is also useful for comparing relative response across treatment groups when the same cell type, density, exposure time, and readout procedure are maintained.

Its limitations matter. MTT is not inherently continuous, the crystals require a dissolution step, and metabolic stimulants or inhibitors can alter the signal independently of cell survival. Resazurin-based assays may be more convenient for repeated measurements, while ATP-based luminescence can offer a different sensitivity profile. Neither alternative automatically replaces proper controls. Select MTT when a robust colorimetric endpoint and accessible instrumentation are priorities, then validate mechanism-sensitive conclusions with an orthogonal measurement.

Troubleshooting and optimization tips

Weak signal or compressed dynamic range

• Check cell density: If untreated wells are near the lower detection limit, increase seeding density or extend the growth period while keeping the culture sub-confluent. If all wells are saturated, reduce density or shorten MTT exposure.
• Verify reagent integrity: Use a freshly prepared working solution and minimize repeated warming, light exposure, and long-term solution storage. Compare a new preparation with a retained control plate before changing biological conditions.
• Improve crystal dissolution: Incomplete solubilization creates patchy absorbance and underestimates viability. Confirm that the medium has been removed consistently, then mix until no visible crystals remain.

High variability or unexpected viability values

Edge wells can evaporate more rapidly than interior wells, changing effective concentration and cell density. Fill unused perimeter wells with sterile buffer or medium when compatible with the plate format, and avoid placing all replicates in one location. Check pipette calibration, mixing order, irradiation uniformity, and timing between reagent addition and reading.

Unexpectedly high viability may indicate that the exposure interval is too short, the treatment concentration is insufficient, or the formulation prevents effective cellular access. Unexpectedly low viability can reflect solvent toxicity, excessive irradiation, prolonged MTT exposure, or a formulation that directly interferes with the chemistry. Run cell-free formulation blanks and solvent-matched controls before attributing the result to biology.

Interpreting a metabolic shift correctly

If MTT changes while cell counts remain stable, describe the result as altered metabolic activity rather than immediate cell killing. Conversely, a stable MTT signal does not exclude changes in clonogenic potential or delayed apoptosis. For the caged-drug chemoradiation workflow, pair the colorimetric result with evidence of drug localization and treatment timing so that reduced absorbance is not overinterpreted as proof of nuclear drug release.

Future outlook

The most defensible future use of MTT is as a standardized screening layer within multiparametric workflows. In radiation-triggered delivery studies, consistent controls can distinguish carrier effects, irradiation effects, and activated-drug effects before more specialized imaging or in vivo work is pursued. The reference study illustrates why this separation matters: localized activation and nuclear relocalization are mechanistic claims, whereas MTT primarily reports the downstream metabolic consequence. Maintaining that distinction will improve reproducibility and make colorimetric data more useful for translational decision-making.

Related MTT guidance for assay planning

For hands-on troubleshooting, Optimizing Cell Viability Assays with MTT complements this workflow with additional discussion of plate setup, assay variability, and interpretation. For study design and translational framing, MTT in Translational Cancer Research extends the present application by connecting metabolic readouts with mechanistic validation and technology comparison. MTT is intended for scientific research use only and is not a diagnostic or medical product.